Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
暂无分享,去创建一个
Daniel L Baker | Abby L Parrill | D. Baker | A. Parrill | Samantha B. Gacasan | Catrina D Mize | Ashley M Abbott | Samantha B Gacasan | Ashley M. Abbott
[1] Y. Kishi,et al. Autotaxin Stabilizes Blood Vessels and Is Required for Embryonic Vasculature by Producing Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.
[2] A. L. Howard,et al. Characterization of non-lipid autotaxin inhibitors. , 2010, Bioorganic & medicinal chemistry.
[3] E. J. North,et al. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. , 2010, Journal of medicinal chemistry.
[4] H. Bostic,et al. Optimization of a pipemidic acid autotaxin inhibitor. , 2010, Journal of medicinal chemistry.
[5] Suk Woo Nam,et al. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells , 2000, Oncogene.
[6] D. Baker,et al. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts , 2010, Expert opinion on therapeutic patents.
[7] H. Nishimasu,et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators , 2011, Nature Structural &Molecular Biology.
[8] Z. Zhao,et al. Expression of autotaxin mRNA in human hepatocellular carcinoma. , 1999, Chinese medical journal.
[9] G. Mills,et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production , 2002, The Journal of cell biology.
[10] M. Bollen,et al. Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts , 2010, PloS one.
[11] Yu Zeng,et al. Gene expression profiles of lysophosphatidic acid‐related molecules in the prostate: Relevance to prostate cancer and benign hyperplasia , 2009, The Prostate.
[12] K. Fukuzawa,et al. Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase* , 2002, The Journal of Biological Chemistry.
[13] A. Kehlen,et al. IL‐1β‐ and IL‐4‐induced down‐regulation of autotaxin mRNA and PC‐1 in fibroblast‐like synoviocytes of patients with rheumatoid arthritis (RA) , 2001 .
[14] W. Xie,et al. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid , 2008, Neuroscience.
[15] G. Mills,et al. The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.
[16] A. Parrill,et al. Molecular mechanisms of lysophosphatidic acid action. , 2003, Progress in lipid research.
[17] G. Ferry,et al. Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal , 2007, FEBS letters.
[18] W. Moolenaar. LPA: a novel lipid mediator with diverse biological actions. , 1994, Trends in cell biology.
[19] D. Baker,et al. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents. , 2008, Anti-cancer agents in medicinal chemistry.
[20] G. Ferry,et al. Molecular pharmacology of adipocyte-secreted autotaxin. , 2008, Chemico-biological interactions.
[21] Chenqi Zhao,et al. Autotaxin and lysophospholipids in rheumatoid arthritis. , 2010, Current opinion in investigational drugs.
[22] K. Kikuchi,et al. Inhibition of Autotaxin by Lysophosphatidic Acid and Sphingosine 1-Phosphate* , 2005, Journal of Biological Chemistry.
[23] G. Ferry,et al. Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation , 2003, The Journal of Biological Chemistry.
[24] A. Parrill. Lysophospholipid interactions with protein targets. , 2008, Biochimica et biophysica acta.
[25] L. Liotta,et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. , 1992, The Journal of biological chemistry.
[26] H. Ueda,et al. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine , 2010, Molecular pain.
[27] Lin Ma,et al. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain , 2008, Molecular pain.
[28] J. Aoki,et al. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. , 2010, Biochimie.
[29] D. Egan,et al. Discovery and optimization of boronic acid based inhibitors of autotaxin. , 2010, Journal of medicinal chemistry.
[30] Hyun Cheol Chung,et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells , 2002, Clinical & Experimental Metastasis.
[31] D. Fishman,et al. Roles of LPA in ovarian cancer development and progression. , 2009, Future oncology.
[32] C. Mummery,et al. Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development , 2006, Molecular and Cellular Biology.
[33] G. Prestwich,et al. Regulation of Lysophosphatidic Acid Receptor Expression and Function in Human Synoviocytes: Implications for Rheumatoid Arthritis? , 2008, Molecular Pharmacology.
[34] Anastassis Perrakis,et al. Structural basis for substrate discrimination and integrin binding by autotaxin , 2010, Nature Structural &Molecular Biology.
[35] K. Jakobs,et al. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. , 2007, Biochimica et biophysica acta.
[36] G. Prestwich,et al. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. , 2006, Organic letters.
[37] K. Meier,et al. Lysophospholipase D and its role in LPA production. , 2004, Cellular signalling.
[38] H. Dralle,et al. Expression, regulation and function of autotaxin in thyroid carcinomas , 2004, International journal of cancer.
[39] Daniel L Baker,et al. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. , 2008, Bioorganic & medicinal chemistry.
[40] G. Prestwich,et al. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. , 2008, Biochimica et biophysica acta.
[41] David A. Egan,et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation , 2010, Proceedings of the National Academy of Sciences.
[42] J. Brown,et al. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival , 2004, Journal of cellular biochemistry.
[43] M. Bollen,et al. Nucleotide Pyrophosphatases/Phosphodiesterases on the Move , 2000, Critical reviews in biochemistry and molecular biology.
[44] J. Gierse,et al. A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation , 2010, Journal of Pharmacology and Experimental Therapeutics.
[45] Duane D. Miller,et al. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. , 2006, Bioorganic & medicinal chemistry letters.
[46] G. Mills,et al. Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and Metastasis* , 2006, Journal of Biological Chemistry.
[47] T. Macdonald,et al. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[48] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[49] J. Chun,et al. Genetics and cell biology of lysophosphatidic acid receptor‐mediated signaling during cortical neurogenesis , 2004, Journal of cellular biochemistry.
[50] Lin Ma,et al. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX‐mediated conversion to LPA, an initiator of neuropathic pain , 2008, Journal of neurochemistry.
[51] D. Im. New intercellular lipid mediators and their GPCRs: an update. , 2009, Prostaglandins & other lipid mediators.
[52] P. Neiman,et al. Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun , 2004, Oncogene.
[53] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[54] L. Liotta,et al. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. , 1994, The Journal of biological chemistry.
[55] D. Stainier,et al. Lipid receptors in cardiovascular development. , 2003, Annual review of physiology.
[56] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[57] Y. Kishi,et al. Autotaxin Is Overexpressed in Glioblastoma Multiforme and Contributes to Cell Motility of Glioblastoma by Converting Lysophosphatidylcholine TO Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.
[58] G. Prestwich,et al. α‐Substituted Phosphonate Analogues of Lysophosphatidic Acid (LPA) Selectively Inhibit Production and Action of LPA , 2007, ChemMedChem.
[59] P. Valet,et al. Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase. , 2007, Biochimica et biophysica acta.
[60] K. Sano,et al. Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. , 1997, Cancer research.
[61] Tanja Woyke,et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. , 2005, Neoplasia.
[62] D. Braddock,et al. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion , 2008, Molecular Cancer Therapeutics.
[63] W. Moolenaar. Bioactive lysophospholipids and their G protein-coupled receptors. , 1999, Experimental cell research.